CBIO Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Crescent Biopharma, Inc. had $10.8M of revenue in fiscal 2025. Over five years, revenue changed +1.3% a year on average.
Last close Β· Oct 23, 2026
$12.82
2.4%Hi! I read Crescent Biopharma, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Does it make a profit?
β1,419.6%
No. It lost money last year.
Does profit turn into cash?
β668.1%
No. It spent more cash than it brought in.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Crescent Biopharma, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 11 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 14, 2026 | Q2 '26 | After the market closes | 8-K β |
| Apr 29, 2026 | Q1 '26 | After the market closes | 8-K β |
| Feb 26, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 6, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Jul 29, 2025 | Q2 '25 | Time not announced | 8-K β |
| May 14, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Feb 13, 2025 | Q4 '24 | After the market closes | 10-K β |
| Nov 13, 2024 | Q3 '24 | After the market closes | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Crescent Biopharma, Inc. had $10.8M of revenue in fiscal 2025. Over five years, revenue changed +1.3% a year on average. Its operating margin was β1,407.5%: of every 100 in sales, about β1,408 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Crescent Biopharma, Inc. lost $154M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$72.5M in fiscal 2025, β668.1% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Crescent Biopharma, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $90.3M | $47.9M | $41.8M | $34.8M | $213M |
| Interest coverage | β | β | β | β | β69.9x |
| Current ratio | 7.7x | 5.7x | 6.4x | 3.6x | 6.6x |
| Quick ratio | 7.7x | 5.7x | 6.4x | 3.6x | 6.6x |
| Total assets | $94.3M | $51.8M | $45.3M | $35.6M | $240M |
| Total liabilities | $12.7M | $8.9M | $6.9M | $47.1M | $37.3M |
| Shareholders' equity | $81.6M | $42.9M | $38.4M | β$15.5M | $203M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | β / 6 | 1 / 7 | 1 / 7 | 3 / 7 | β / 6 | β / 5 |
| Accruals ratio | β4.9% | β4.1% | β2.9% | β3.1% | β7.6% | β5.0% | β0.3% | β4.2% | β16.8% | β59.7% |
| Altman Z'' | β3.69 | 14.59 | 24.57 | 10.21 | 5.51 | β5.19 | β22.18 | β27.47 | β4.90 | 4.59 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.0M | β | β | β | $10.2M | $1.2M | $0.1M | $0.0M | β | $10.8M |
| Research and development | $23.3M | $24.1M | $40.1M | $47.0M | $44.9M | $47.5M | $28.4M | $20.1M | $14.3M | $138M |
| Operating income | β$31.9M | β$33.9M | β$51.5M | β$61.4M | β$51.5M | β$63.4M | β$47.4M | β$39.3M | β$40.0M | β$153M |
| Interest expense | β | β | β | β | β | β | β | β | β | $2.2M |
| Pretax income | β | β | β | β | β | β | β | β | β | β$152M |
| Income tax | β | β | β | β | β | β | β | β | β | $2.0M |
| Net income | β$31.8M | β$33.3M | β$48.3M | β$57.9M | β$51.0M | β$63.4M | β$46.7M | β$36.9M | β$37.9M | β$154M |
| Net income to common | β | β | β | β | β | β | β | β | β | β$133M |
| Diluted EPS | β$1.50 | β$1.13 | β$1.18 | β$1.34 | β$1.12 | β$1.23 | β$0.89 | β$0.58 | β$0.59 | β |
| Diluted shares | 0.02B | 0.03B | 0.04B | 0.04B | 0.05B | 0.05B | 0.05B | 0.06B | 0.06B | β |
| Cash flow | ||||||||||
| Cash from operations | β$29.7M | β$29.8M | β$43.3M | β$52.0M | β$39.2M | β$57.5M | β$46.5M | β$34.9M | β$31.1M | β$71.5M |
| Capital expenditure | $0.7M | $0.3M | $0.1M | $0.1M | $0.1M | $0.0M | $0.1M | $0.0M | $0.0M | $0.9M |
| Free cash flow | β$30.4M | β$30.1M | β$43.5M | β$52.1M | β$39.3M | β$57.5M | β$46.5M | β$34.9M | β$31.1M | β$72.5M |
| Depreciation and amortization | $0.2M | $0.3M | $0.3M | $0.3M | $0.3M | $0.3M | $0.2M | $0.2M | $0.0M | $0.1M |
| Stock-based compensation | $3.0M | $3.8M | $4.6M | $6.2M | $6.9M | $6.1M | $3.9M | $3.5M | $4.7M | $13.3M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $40.0M | $124M | $210M | $158M | $137M | $90.3M | $47.9M | $41.8M | $34.8M | $213M |
| Current assets | $40.5M | $127M | $212M | $163M | $138M | $90.8M | $50.7M | $43.8M | $34.8M | $237M |
| Current liabilities | $6.3M | $8.2M | $8.8M | $11.0M | $12.4M | $11.8M | $8.9M | $6.8M | $9.6M | $36.1M |
| Property and equipment, net | $1.1M | $1.1M | $1.0M | $0.8M | $0.6M | $0.4M | $0.2M | β | $0.0M | $0.8M |
| Total assets | $42.4M | $129M | $215M | $168M | $143M | $94.3M | $51.8M | $45.3M | $35.6M | $240M |
| Total liabilities | $7.1M | $8.9M | $9.4M | $13.8M | $14.6M | $12.7M | $8.9M | $6.9M | $47.1M | $37.3M |
| Preferred stock | β | β | β | β | β | β | β | β | β | $4.0M |
| Shareholders' equity | $35.3M | $120M | $205M | $154M | $128M | $81.6M | $42.9M | $38.4M | β$15.5M | $203M |
| Margins | ||||||||||
| Operating margin | β172,505.4% | β | β | β | β506.8% | β5,470.5% | β63,204.4% | β392,753.0% | β | β1,407.5% |
| EBITDA margin | β171,475.7% | β | β | β | β504.2% | β5,447.7% | β62,928.3% | β391,220.0% | β | β1,406.8% |
| Net margin | β171,944.9% | β | β | β | β502.1% | β5,468.8% | β62,251.7% | β368,994.0% | β | β1,419.6% |
| FCF margin | β164,516.2% | β | β | β | β386.8% | β4,958.1% | β62,055.6% | β349,013.0% | β | β668.1% |
| Returns | ||||||||||
| Return on capital employed | β88.5% | β28.2% | β25.0% | β39.1% | β39.5% | β76.9% | β110.4% | β102.1% | β154.0% | β74.7% |
| Return on equity | β90.1% | β42.9% | β29.7% | β32.2% | β36.1% | β60.5% | β75.0% | β90.7% | β330.3% | β164.2% |
| Return on assets | β75.0% | β38.9% | β28.1% | β30.2% | β32.8% | β53.5% | β63.9% | β76.0% | β93.6% | β111.6% |
| Return on tangible equity | β90.1% | β27.8% | β23.5% | β37.5% | β39.8% | β77.7% | β108.8% | β96.1% | β | β65.7% |
| Growth | ||||||||||
| Revenue growth | β | β | β | β | β | β88.6% | β93.5% | β86.7% | β | β |
| Share count change | β | 38.3% | 39.6% | 5.4% | 5.7% | 12.5% | 2.1% | 20.6% | 1.8% | β |
| Financial health | ||||||||||
| Interest coverage | β | β | β | β | β | β | β | β | β | β69.9x |
| Current ratio | 6.4x | 15.6x | 24.2x | 14.8x | 11.1x | 7.7x | 5.7x | 6.4x | 3.6x | 6.6x |
| Quick ratio | 6.4x | 15.6x | 24.2x | 14.8x | 11.1x | 7.7x | 5.7x | 6.4x | 3.6x | 6.6x |
| Capital allocation | ||||||||||
| Capex / revenue | 3,806.5% | β | β | β | 0.7% | 1.3% | 112.3% | 214.0% | β | 8.5% |
| Stock comp / revenue | 16,025.9% | β | β | β | 67.9% | 524.9% | 5,143.5% | 35,245.0% | β | 122.6% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | β | β | β | 1.0 | 1.0 | 3.0 | β | β |
| Altman Z'' | β3.7 | 14.6 | 24.6 | 10.2 | 5.5 | β5.2 | β22.2 | β27.5 | β4.9 | 4.6 |
| Accruals ratio | β4.9% | β4.1% | β2.9% | β3.1% | β7.6% | β5.0% | β0.3% | β4.2% | β16.8% | β59.7% |
Source: SEC EDGAR XBRL filings (CIK 0001253689). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
